Statistics

Total Visits

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens61

Select a period of time:

Number of views in the range

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens21

Views

Views
October 20253
November 20254
December 20251
January 20261
February 20260
March 202612
April 20260
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States13
Brazil2
Argentina1
France1
United Kingdom1
Hungary1
Tunisia1
Venezuela1
 

Top cities views

Views
San Jose10
Ciudad Guayana1
Curitiba1
North Bergen1
Río Gallegos1
Tunis1
Wenceslau Guimarães1